Tildrakizumab: A Long-Acting Biologic Therapy for Moderate-to-Severe Plaque Psoriasis

　　Tildrakizumab is a humanized IgG1/κmonoclonal antibody that selectively neutralizes the p19 subunit of interleukin-23(IL-23).It is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.By inhibiting the IL-23/Th17 pathway,it provides sustained control over inflammatory responses.

　　Clinical Efficacy

　　Data from the pivotal Phase III reSURFACE trials demonstrate robust efficacy.At week 12,approximately 75%of patients receiving the 100 mg dose achieved a PASI 75 response,and 55%achieved PASI 90.Efficacy deepened by week 28,with PASI 90 rates climbing to 70%and over 60%of patients achieving complete skin clearance(PASI 100).

　　A key advantage of tildrakizumab is its durability and convenience.Following an initial induction regimen at weeks 0 and 4,maintenance dosing occurs once every 12 weeks.Long-term data show that over 80%of patients maintain a PASI 90 response after two years of treatment.The drug is also effective against difficult-to-treat areas such as the scalp,nails,and palmoplantar regions.

　　Safety Profile

　　Tildrakizumab exhibits a favorable safety profile compared to other biologics.It does not appear to increase the risk of tuberculosis reactivation;baseline screening for latent TB is recommended,but prophylactic antitubercular treatment is generally not required unless risk factors are present.The most common adverse event is mild upper respiratory infection(approx.10%).

　　Five-year safety data have not shown an increased risk of non-melanoma skin cancer or lymphoma.Injection site reactions are rare(<2%),and unlike some同类药物,it carries no boxed warning for major adverse cardiovascular events.

　　Limitations and Considerations

　　The primary limitation is the onset speed.Compared to IL-17 inhibitors(which often work within 4 weeks),tildrakizumab has a median time to PASI 75 of 8–12 weeks.Therefore,for patients requiring rapid disease control(e.g.,erythrodermic psoriasis),alternative agents may be preferred.

　　Furthermore,tildrakizumab is currently approved only for plaque psoriasis.Its efficacy in psoriatic arthritis has not been established.Patients with comorbid arthritic symptoms should be treated with TNF-αinhibitors,IL-17 inhibitors,or JAK inhibitors.

　　Administration and Special Populations

　　Serious hypersensitivity reactions(e.g.,urticaria,angioedema)are rare(<0.5%);however,monitoring for 30 minutes post-injection is advised.Due to immunomodulatory effects,live vaccines(e.g.,MMR,varicella)are contraindicated during treatment and for at least five months after discontinuation.Inactivated vaccines(e.g.,influenza,pneumococcal)are safe and encouraged.

　　Tildrakizumab is not metabolized via the CYP450 system,minimizing drug-drug interaction risks.It is considered relatively safe during lactation due to minimal secretion into breast milk.No dose adjustment is needed for hepatic or renal impairment.Use during pregnancy should be based on a risk-benefit assessment.